Replies to post #1907 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ABBV’s Mavyret_2020_guidance=$1.9B—implying ~$560M in 4Q20. (Source: Today’s 3Q20 CC.)

[DewDiligence]

ABBV 4Q20 Mavyret sales=$481M, +16% QoQ, -23% YoY:

https://news.abbvie.com/news/press-releases/abbvie-reports-full-year-and-fourth-quarter-2020-financial-results.htm

The $481M consisted of: $420M US; $461M ex-US.

Mavyret full-year 2020 sales were $1.83B, slightly below ABBV’s most recent guidance of $1.9B.